Docket No.: 022290.0120PTUS

(PATENT)

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Catherine Castan et al.

Application No.: 10/510,643

Confirmation No.: 1869

Examiner: C. E. Helm

Filed: May 23, 2005

Art Unit: 1615

For: ORAL PHARMACEUTICAL FORMULATION

IN THE FORM OF AN AQUEOUS

SUSPENSION OF MICROCAPSULES FOR THE MODIFIED RELEASE OF ACTIVE

PRINCIPLE(S)

# **DECLARATION OF CATHERINE CASTAN**

- 1. My name is Catherine CASTAN.
- 2. I have been an employee of Flamel Technologies, S.A. since 1992.
- 3. My position at Flamel Technologies S.A. is Director of R&D Oral Dosage Forms.
  - 4. I have a Ph.D. in Polymer Chemistry.
  - 5. I have worked in the area of pharmaceutical compositions for 21 years.
- 6. I consider myself to be one of skill in the art of oral pharmaceutical compositions for modified release of active principles.
- 7. I reviewed the Office Action that issued on December 7, 2009, for U.S. Application No. 10/510,643.
- 8. I also reviewed U.S. Patent No. 4,902,513 ("Carvais") and U.S. Patent No. 6,022,562 ("Autant"), references cited by the Examiner in 35 U.S.C. § 103(a) rejections of Application No. 10/510,643.
- 9. In reviewing the Office Action, it is my understanding that the Examiner is alleging that it would have been obvious to one of ordinary skill in the art to employ coated particles of Autant et al. as the microcapsules in the sustained release, drug saturated suspension of Carvais. *See*, Office Action at page 9.

- 10. As one of skill in the art, I believe the claimed invention has unexpected and surprising properties because the claimed suspension of microcapsules in an aqueous liquid phase is found to confer the unexpectedly superior claimed release profile upon the microcapsules.
- 11. At the time of the application, one of ordinary skill in the art would have known that suspensions of microcapsules, including coated microcapsules, suffered from stability problems.
- 12. While this was known to those of skill in the art, further evidence of this is found in Santus et. al. (EP 0359195, page 2) from 1989 which stated that in the preparation of controlled release liquid pharmaceutical compositions, the "problem is the difficulty of obtaining controlled release liquid preparations apt to maintain for long times the release characteristics of the pharmaceutical substances contained.[...] It may explain why as far as we know, only few controlled release liquid systems are known up to now, and among them, only one is actually commercially available". In 2002, the stability of the release profile in controlled release liquid suspensions was still perceived as a problem difficult enough to explain limited commercial success. See excerpt from the reference textbook by Banks et al., "Modern pharmaceutics, Volume 121", 4th Edition, Informa Health Care, pp. 396-8 (2002). See Appendix. Page 397 states: "The formulation of oral sustained-release suspensions has resulted in only limited success due to the difficulty in maintaining the stability of sustained release particles when present in liquid system." As such, it was unexpected for the coated microcapsules of the claimed invention to provide the beneficial stability characteristics as claimed. To the best of my knowledge, less than five controlled release liquid suspension products are commercially available today, indicating that the problem of stability is still current.
- 13. Page 397 of the Appendix to Banks et al. further states: "Formulation techniques, such as coated beads, drug impregnated wax matrix, microencapsulation, and ion exchange resin, have been used for this purpose". As such, it was unexpected for techniques intended to create sustained release particles, such as those listed on Page 397, to maintain a stability in liquid systems.
- 14. One of skill in the art would also expect that in a coated microcapsule where the coat contains water soluble materials, the soluble components would dissolve in water.
- 15. As such, it was unexpected that a microcapsule with a coating containing water soluble materials would maintain coating permeability when placed in an aqueous solution for 10 days.

- Therefore, one of ordinary skill in the art at the time of the invention would not 16. have foreseen that the claimed coating composition would produce a release profile in an aqueous liquid on day ten similar to the release profile on day zero.
- Accordingly, Carvais in view of Autant could not teach the unexpected 17. stability of the release profile as claimed: "wherein the in vitro release profile of the suspension of microcapsules in an aqueous liquid phase on day ten is similar to the release profile on day zero, as measured using a type II apparatus according to the European Pharmacopoeia 3rd edition, in a phosphate buffer medium of pH 6.8, at a temperature of 37°C".
- 18. I declare that all statements made of my own knowledge are true and all statements made on information and belief are believed to be true. I make this declaration with the understanding that willful false statements and the like are punishable by fine or imprisonment, or both (18 U.S.C. 1001) and may jeopardize the validity of the patent application.

Catherine CASTAN

Date

## Appendix:

# Handbook Banks et al., "Modern pharmaceutics, Volume 121", 4th Edition, Informa Health Care (2002)

Google livres on suspension relates Companies livres Ma bistothicus : Corrente Modern pharmaceutics, Volume 121 Far Office & Banker Chroscopher T. Propes & & II Derter vermen. mile R'aimmenne Freseniston benerale : Aperçu Résultat 1 sur 1 cans de livre dour oral suspension extended release Accesses Modern pharmoceutics 396 the mean free diffusion path of the solute molecules and may thus promote the particle growth.

Polymorphism refers to the different internal crystal structures of a chemically identical compound. Drugs may undergo a change from one netastable polymorphic form to a more stable polymorphic form. Also, the crystal habit might change due to the degree of solvation or hydration. The formation of distance new erystalline enables during storage is possible. For example, an originally subjects the general particle enables during storage is possible. For example, an originally subjects along in a suspension may rapidly or slowly form a hydrate. These various forms may exhibit different solubilities, melting points, and x-tay diffraction potterns. In the preparation of suspensions using precipitation methods, the solvent and the rate of cooling are important factors determining the type of polymorphic obtained.

Various drugs are known to exist in different polymorphic forms (e.g., cortisone and predissolent.) The rate of conversion from a metastable into the stable form is an important criteria to be considered with respect to the shelf life of a pharmaceutical product. Polymorphic changes fave also been observed during the manufacture of steroid suspensions. When steroid products are subjected to dury heat sterilization, subsequent rehydration of large, needle-like crystals. A similar effect may be produced by subject formation of large, needle-like crystals, a similar effect may be produced by subject formation of large, needle-like crystals, a similar effect may be produced by subject morphous or glassy forms of a ding etaility significantly greater initial solubility in water than their corresponding crystalline forms [84]. In addition, size reduction by crushing and granding can produce parieles whose different surfaces exhibit high or tow dissolution rates. This effect can be correlated to differences in the free surface energy introduced during comminution. 003 535061901 EXECCED the mean free diffusion path of the solute molecules and may thus promote the particle wadowii - Férral ve commentes : 1-14: 0-7.617.14:03 • Se procurer ce livre Ir forms Health Care A30506 Depte Trouvez les librariles prés de chez Total tell cardenia a Time for successiving a Lass commercials Global Labeling Solution Get ready for FIM and SPLIPER with Schema ST4 www.schema.de dissolution rates. This effect can be cortelated to differences in the free surface energy introduced doring commination.

To prevent crystal growth and possible changes in particle size distribution, one or more of the following procedures and techniques may be employed [9,29]: (a) selection of particles with a narrow size range; (b) selection of a more stable crystalline form of the drug; (c) avoidance of the use of high-energy milling during particle size reduction; (d) incorporation of a wetting agent (e.g., surfactant) and/or a protective colloid (e.g., cellulose derivatives forming film barriers around the particles); (e) increase of the viscosity of the whitele to retard particle dissolution and subsequent crystal growth; and (f) avoidance of temperature extremes during storage. ma heath Care Error raiseur D. Pharmaceutical Suspensions In the preparation of physically stable pharmaceutical suspensions, a number of formulation components can be incorporated to maintain the solid particles in the dispersed state. These substances can be classified as (a) components of the suspending system. Including wetting agents, dispersants or defloce/ulting agents, flooculating agents, flooculating agents, flooculating agents, flooculating agents, flooculating agents, and thickeners, and (b) components of the suspending vehicle (external phase), including plf-control agents and buffers, osmotic agents, coloring/flavoring agents, preservatives, and liquid vehicles. The components of each category are individually selected for their use in the preparation of oratily, topically, or parenterally administered systemsions.

3713589



Erésenter on panérsia : Aperço

S S II Tron ien omeren "

保育和器 Résultat 1 sur 1 pars de l'ore sour prof suspension extended release mile Bicementen Effacer to represente 1/2

لتنجه

Ē

015 3.508 58 01 6X8 1060 seesed • filtrativity options

Emple divine

Se procurer ce livre Infarma maabin Care Similar ATRO FORM Captie Travelante la travel avec de ches. Television in

Livres sur des suists connezes





Tols expanses while

Pharms granulation
Natural remodies, pharmadestipale, floor euconoments, granulation etc.

Marchaelterine de la companyation e



### Disperse systems 397

Disperce systems 397

Orally administered suspensions containing a wide class of active ingredients (e.g., ambionics, antacids, radiopaque agents) are of major commercial importance. The solidal content of an word suspension may vary considerably. For example, antibiotic preparations may contain (23-500 mg solid drug per) and or a teasponofid dose, while a drup encountrate may provide the same amount of drug in unity 1-2 ml. Antacid or radiopaque suspension take onemain relatively high amounts of suspended material for until administration. The suspending vehicle can, for example, he a syrup, sorbitol solution, or gun-thickened water with added artificial sweetness. Take and mouthfeel are important considerations when formulating oral suspensions.

Meny multiotic drugs are unstable in the presence of an aspecus vehicle and, therefore, are frequently supplied as dry powder makiners for reconstitution at the time of dispensing. Generally, this type of product is either a powder existere or a completelyferatially granulated product, which upon dilution and aptision with a specified quantity of vehicle (e.g., water) results in the formation of a suspension stituble for administration [90]. The preparation is to spically designated in the USF by a ritle of the form "For Oral Suspension," whereas the ready-to-use suspension preparations are simply designated as "Oral Suspension," The dry mits products often contain duege, colorants, flavorants, sweeteners (e.g., sucrose or sodium saccharin, stabilizing agents (e.g., cliric acid, sodium clirate), suspension gents (e.g., guer gum, xanihan gum, mentifyicellitose), and preservatives (e.g., paraberts, sodium benzoate).

The formulation of ord sestained-volence suspensions has resolted in only limited success due to the difficulty in matinatining the stability of sustained clean paint, and accounts of the difficulty in matinatining the stability of sustained lease, during materianced wax matrix, microexcapputation, and in securious complex, with particle continely has reso

3713589

a a 🗓 Termana mulikan -

THE E

Résultat 1 sur 1 cans de levre cour oral suspension extended release

m.a: G'Cionantina Effeceriementerore Signal

ioral suspension exerces

olg words - <del>Secuel Lauring Sold</del> Controlled Charles and Seadles -

Sa procurer se livre Informa Haalin Care Approx Actation France <u>Decre</u> Trouved les libre nes orde de ches NOVE

Tale es vetagos :

Livres sur des sujets connexes



Transet sover loves :

Lens commercials Health Economics
Disease burden, cost effectiveness
modeling, HTA possier services
www.orestivicestics(com

informa

Pages attores san electronomics officer paker (RE Editable)

### Modern pharmocentics 398

In contrast, parenteral supernsions have relatively low solids contents, usually between 9.5 and 5%, with the exception of insolvble forms of pedicillin in which concentrations of the unithinic may exceed 30%. These sterile preparations are designed for intransecular, intraderiously, intraderiously, intraderiously, or subcouncous injection. Syringeability is an important factor to be taken into consideration with injectable dosage forms. The viscosity of a parenteral suspension should be refliciently low to facilitate injection. Common suspending vehicles include preserved istoroic saline solution or a parenterally acceptable vegetable oil. Ophthalmic and uptue suspensions that are instilled into the expector must also be prepared in a sterile manner. The vehicles are essentially isotonic and aqueous in composition. The reader should refer to Chapter 12 for further discussion on parenteral products.

### E. Methods of Evaluating Suspensions

Suspensions are generally evaluated with respect to their particle size, electrokinetic assignments are generate evaluated with respect to their particle size, electrolymetic properties (exe potential), and finelogical characteristics. A detailed discussion on the methodsheehniques and relevant instrumentation is given in Sec. VII. A number of evaluating methods done specifically with suspension dosage forms, such as sedimentation volume, redispersibility, and specific gravity measurements, will be treated in this section.

In this section. The sedimentation volume of a pharmaceutical suspension can be evaluated using simple, inexpensive, graduated, cylindrical graduates (100–1000 mL), it is defined as the ratio of the equilibrium volume of sediment,  $V_e$  to the total volume of the suspension,  $V_e$ .  $F = \frac{V_e}{V_o}$ (12)

$$F = \frac{V_w}{V_A}$$
(12)

The value of F ranges between 0 and 1 and increases as the volume of suspension that appears occupied by the sediment increases. For example, if 100 mt. of a well-shaken test formulation is placed in a graduate cylinder and the final height of the sediment is at the 20 mt. Inc., then F is 0.2. It is normally found that the greater the value of F, the more stable the product.

When F=1, no sediment is apparent and caking is absent, and the suspension is considered exhetically pleasing. This method of evaluation is quite useful in determining the physical stability of suspensions. It can be used to determine the settling rates of focculated and deflocutated suspensions by making periodic measurements of sedimentation height. Tingstad [96] indicated that a flucculated suspension that settles to a level that is 90% of the initial suspension height (F=0.9) and no further is probably satisfactory.

a level that is 90% or one union sequences assistances.

The degree of fleeculation,  $\beta_i$  is defined as the ratio of the sedimentation volume of the flocculated suspension,  $F_i$  to the sedimentation volume of the suspension when deflocculated,  $F_i$ . It is expressed as:  $\alpha = \frac{F_i}{F_i}$ (13)

$$\beta = \frac{F}{F_{\infty}} \tag{13}$$